Prestige Consumer Healthcare saw its stock fall sharply in morning trading after the company released its fiscal fourth-quarter 2026 results following the market close. Shares dropped 12.70% to $45.23 as investors reacted to a combined shortfall on both revenue and earnings.
The company reported Q4 revenues of $281.6 million and full-year fiscal 2026 revenues of $1,088.7 million. Management also announced an agreement to acquire LaCorium Health. Despite the acquisition plan, Q4 financials showed deteriorating profitability - gross profit for the quarter fell 14.0% year-over-year while operating profit declined 14.6% compared with the prior-year period. The company said diluted earnings per share were below analyst expectations, reflecting the softer top-line performance.
Prestige attributed most of the revenue shortfall to restricted supply capacity for its Clear Eyes products in North America. The company also reported that its international business was negatively affected by shipping disruptions in the Middle East.
Looking ahead, the company issued fiscal 2027 guidance that calls for organic revenue growth and adjusted diluted EPS growth of only 1% to 3%, excluding the impact of acquisitions. Investors regarded that range as underwhelming given the scale of the fiscal 2026 decline.
On the analyst front, Oppenheimer lowered its rating on the stock from "Outperform" to "Perform," removing a notable institutional endorsement after an earlier price-target reduction earlier in the month. Insider transactions have shown a negative tilt as well, with zero insider purchases and four insider sales recorded over the past six months.
The price action in Prestige diverged markedly from broader market performance on the same day. The S&P 500 rose 0.61%, the Dow Jones Industrial Average gained 0.50%, and the NASDAQ advanced 0.70%, indicating the move in Prestige shares was driven by company-specific issues rather than general market weakness.
Shares had already been trading under pressure ahead of the results, sitting well below their 200-day moving average and more than 42% beneath their 52-week high of $89.37 as the company headed into the earnings release.
Company leadership emphasized operational responses to the challenges. CEO Ron Lombardi said the company plans to "leverage our leading portfolio, diverse supply chain, and agile operating model to manage and mitigate" cost pressures in fiscal 2027. Despite that assurance, investors appeared unconvinced that improvements in eye care supply or growth driven by acquisitions will be sufficient to reverse the recent financial decline in the near term.
Summary of the core developments:
- Q4 revenue: $281.6 million.
- Fiscal 2026 revenue: $1,088.7 million.
- Q4 gross profit fell 14.0% year-over-year; operating profit declined 14.6% year-over-year.
- Primary revenue headwinds: constrained Clear Eyes supply in North America and shipping disruptions in the Middle East.
- Fiscal 2027 guidance: organic revenue growth and adjusted diluted EPS growth of 1% to 3%, excluding acquisitions.
- Analyst action: Oppenheimer downgraded the stock from "Outperform" to "Perform."
- Insider activity: zero purchases and four sales in the past six months.
The combination of a significant earnings and revenue miss, modest forward guidance, an analyst downgrade, and continued insider selling created a confluence of negative catalysts that drove the stock's steep decline during the morning session.